SOM3355

Completed

SPONSOR

SOM Biotech

PARTICIPANTS

129

The main purpose of this trial is to study the efficacy and safety of SOM3355 in patients with Huntington’s disease. SOM3355, which has been used for hypertension, will be looked at in this phase 2b trial to establish if it helps with chorea in HD. 2 doses and a placebo group will receive the drug orally twice a day for 12 weeks. 129 participants will be recruited.

EHA interview Catherine Scart about SOM3355

SOM3355 - The drug for long term chronic treatment of chorea in Huntington's Disease patients

Ages Eligible
for Study:

21 Years and older (adult)

Sexes Eligible
for Study:

All

Accepts Healthy Volunteers:

No

  • Patients with a diagnosis of Huntington’s Disease determined by a movement disorders expert and confirmed by a number of HTT gene CAG repeats ≥36.
  • UHDRS Total maximal chorea (TMC) score ≥10.
  • UHDRS Total Functional Capacity (TFC) ≥7.
  • Able to walk independently or with minimal assistance.
  • Females of child-bearing potential must use a medically accepted effective method of birth control and should not be breast-feeding.
  • In the opinion of the Investigator, the patient must have adequate support to comply with the entire study requirements.
  • Able and willing to provide written informed consent.
  • Onset of HD symptoms prior to age of 21 years (juvenile forms of HD).
  • HD patients presenting rigid akinesia.
  • Use of other VMAT2 inhibitors such as tetrabenazine, deutetrabenazine, or valbenazine; and use of other antichoreic treatment such as any neuroleptic, or amantadine, memantine, riluzole.
  • Patients who experienced severe depression or suicide attempt in the last 5 years.
  • Severe untreated or under-treated psychiatric illness such as active suicidal ideation or behavior or depression.
  • Patients with a history of, or current, hypotension, bradycardia, or orthostatic hypotension.
  • Patients with hypertension already treated with more than 2 antihypertensive drugs.
  • Other active clinically significant illness, which could interfere with the study conduct, counter-indicate the study treatment, place the patient at risk during the trial, or compromise their study participation.
  • Any significant serious abnormality in the electrocardiogram (ECG), or a known history of long QTc syndrome.
  • Patients with severe hepatic impairment, or with severe renal impairment, or with any other significant abnormality in the physical examination or clinical laboratory results that, in the Investigator’s opinion, would not be compatible with study participation or represent a risk for the patient while in the study.
  • Females who are pregnant or lactating, or who intend to become pregnant during the study period.
  • Patients with allergy under desensitization, with known psoriasis, or a known allergy/hypersensitivity to any ingredients of the trial medication or placebo.
  • History of alcohol or substance abuse in the previous 12 months.
  • Patients participating in any other study, and the use of any investigational therapy.

LOCATIONS

COUNTRIES

France

  • TRIAL SITE:
    Centre Hospitalier Universitaire Angers
  • Address: Angers, France
  • TRIAL SITE:
    CHU Hôpital Henri Mondor (APHP)
  • Address: Créteil, France
  • TRIAL SITE:
    Hôpital Roger Salengro – CHU Lille
  • Address: Lille, France
  • TRIAL SITE:
    Hopital de Hautepierre
  • Address: Strasbourg, France
  • TRIAL SITE:
    Hôpital Purpan – CHU Toulouse
  • Address:Toulouse, France

Germany

  • TRIAL SITE:
    Charité – Universitätsmedizin Berlin
  • Address: Berlin, Germany
  • TRIAL SITE:
    George Huntington Institut
  • Address: Münster, Germany
  • TRIAL SITE:
    Hospital of University of Ulm
  • Address: Ulm, Germany
  • TRIAL SITE:
    kbo-Isar-Amper-Klinikum
  • Address:München,Germany

Italy

  • TRIAL SITE:
    IRCCS Istituto delle Scienze Neurologiche di Bologna
  • Address: Bologna, Italy
  • TRIAL SITE:
    Azienda Ospedaliera Universitaria Federico II
  • Address: Napoli, Italy

TRIAL SITE:
IRCCS Casa Sollievo della Sofferenza
Address: Roma, Italy

  • TRIAL SITE:
    Sant’Andrea University Hospital
  • Address: Roma, Italy

Poland

  • TRIAL SITE:
    Krakowska Akademia Neurologii Sp. z o.o.
  • Address: Kraków, Poland
  • TRIAL SITE:
    Indywidualna Praktyka Lekarska Daniel Zielonka
  • Address: Poznań, Poland

Spain

  • TRIAL SITE:
    Hospital de la Santa Creu i Sant Pau
  • Address: Barcelona, Spain
  • TRIAL SITE:
    Hospital Universitario de Cruces
  • Address: Bilbao, Spain

TRIAL SITE:
Hospital Universitario de Burgos
Address:Burgos, Spain

  • TRIAL SITE:
    Hospital Ramón y Cajal
  • Address: Madrid, Spain

Switzerland

  • TRIAL SITE:
    Universitaetsspital Bern – Inselspital
  • Address: Bern, Switzerland

United Kingdom

  • TRIAL SITE:
    Cambridge University Hospitals NHS Foundation Trust Addenbrooke’s Hospital
  • Address: Cambridge, United Kingdom
  • TRIAL SITE:
    NIHR Wellcome Trust Manchester Clinical Research Facility
  • Address: Manchester, United Kingdom
  • TRIAL SITE:
    Oxford University Hospitals NHS Foundation Trust
  • Address: Oxford, United Kingdom
new FB feed (19)

dictionary:

Phase

Clinical trial phases are different stages of research that assess the safety and effectiveness of a new medical treatment or intervention in humans.

Each phase has a specific goal and involves a different number of participants. Generally, there are 4 phases (I-IV), with Phase I focusing on safety and dosage, Phase II on efficacy and side effects, Phase III on comparing the new treatment with standard treatments, and Phase IV on long-term safety monitoring. 

 
 
new FB feed (19)

dictionary:

SNP-single nucleotide polymorphisms

a single-letter spelling difference in a gene. SNPs, pronounced ‘snips’, are common and most don’t change the function of the gene.

 
new FB feed (19)

dictionary:

at risk

You do not know if you carry the genetic mutation for HD gene 

 
new FB feed (19)

dictionary:

TFC-total functional capacity

A standardized rating scale for function in HD, used to assess capacity to work, handle finances, perform domestic chores and self-care tasks.
Scores range from 0 to 13, with higher scores indicating better functional capacity. 

 
new FB feed (19)

dictionary:

Double-blinded

 means that neither the participant nor the clinical trial doctor can choose or know the group the participant is in until the trial is over. This approach helps to prevent bias.

new FB feed (19)

dictionary:

Open label

A trial in which the patient and doctor know what drug is being used. Open label trials are susceptible to bias through placebo effects.

new FB feed (19)

dictionary:

Gene therapy

a technique that aims to treat or prevent diseases by modifying a person’s genes. It involves introducing, removing, or changing genetic material (DNA or RNA) within a patient’s cells.

new FB feed (19)

dictionary:

UHDRS- Unified Huntington Disease Rating Scale

A standardized neurological examination that aims to provide a uniform assessment of the clinical features of HD

new FB feed (19)

dictionary:

CAG repeat

The stretch of DNA at the beginning of the HD gene, which contains the sequence CAG repeated many times, and is abnormally long in people who will develop HD

new FB feed (19)

dictionary:

Wild-type

the opposite of ‘mutant’. Wild-type huntingtin, for example, is the ‘normal’, ‘healthy’ protein

new FB feed (19)

dictionary:

Tolerabilty

How well a person can handle a treatment without having serious or uncomfortable side effects.

new FB feed (19)

dictionary:

Striatum

Part of the brain that  coordinates multiple aspects of cognition, including both motor and action planning, decision-making, motivation, reinforcement, and reward system.

new FB feed (19)

dictionary:

Randomized allocation

A type of allocation strategy in which participants are assigned to the arms of a clinical trial by chance.

new FB feed (19)

dictionary:

Radioligand

a radioactive substance that binds to a specific target in the body, allowing visualization of that target’s distribution and activity

new FB feed (19)

dictionary:

Protein

Protein builds, maintains, and replaces the tissues in your body. The building blocks of life.

new FB feed (19)

dictionary:

Premanifest / Prodromal

Prior to onset or diagnosis of movement symptoms.

new FB feed (19)

dictionary:

Placebo

A placebo is a dummy medicine containing no active ingredients. The placebo effect is a psychological effect that causes people to feel better even if they’re taking a pill that doesn’t work.

new FB feed (19)

dictionary:

PK - Pharmacokinetics

The movement of drugs through the body

new FB feed (19)

dictionary:

PD - Pharmacodynamics

The body’s biological response to drugs

new FB feed (19)

dictionary:

PET scan

Positron emission tomography which produces detailed 3-dimensional images of the inside of the body.

new FB feed (19)

dictionary:

Neuron

Brain cells that store and transmit information

new FB feed (19)

dictionary:

MRI

Magentic resonance imaging: A technique using powerful magnetic fields to produce detailed images and visualizes the structure of organs, tissues, and bones 

new FB feed (19)

dictionary:

mHTT

Mutant huntingtin protein. The protein produced by the faulty HD gene.

new FB feed (19)

dictionary:

Manifest

after HD diagnosis, or when symptoms are already showing

new FB feed (19)

dictionary:

Longitudinal study

A study where each participant is looked at several times over a time period – unlike a cross-sectional study, where each participant is looked at only once

new FB feed (19)

dictionary:

HTT

one abbreviation for the gene that causes Huntington’s disease. The same gene is also called HD and IT-15

new FB feed (19)

dictionary:

fMRI

functional MRI:As with MRI, a technique using powerful magnetic fields  but focusing on brain function by measuring and mapping changes in blood flow, revealing which areas of the brain are active during specific tasks or cognitive processes

new FB feed (19)

dictionary:

CSF - cerebrospinal fluid

A clear fluid produced by the brain, which surrounds and supports the brain and spinal cord.

new FB feed (19)

dictionary:

Efficacy

A measure of whether a treatment works or not

new FB feed (19)

dictionary:

ASO(Antisense oligonucleotides)

A type of gene silencing treatment in which specially designed DNA molecules are used to switch off a gene

new FB feed (19)

dictionary:

Biomarker

a test of any kind – including blood tests, thinking tests and brain scans – that can measure or predict the progression of a disease like HD. Biomarkers may make clinical trials of new drugs quicker and more reliable

new FB feed (19)

dictionary:

BDNF

Brain-derived neurotrophic factor: a growth factor that may be able to protect neurons in HD.

new FB feed (19)

dictionary:

Allele

one of the two copies of a gene

new FB feed (19)

dictionary:

Plasma

Liquid component of the blood.

new FB feed (19)

dictionary:

Gene

The basic unit of heredity passed from parent to child. Genes are made up of sequences of DNA and are arranged, one after another, at specific locations on chromosomes in the nucleus of cells.